Trial reportFrontiers in endocrinology2025
The impact of age on clinical features and fertility outcomes in patients with polycystic ovary syndrome: a secondary analysis based on the PCOSAct trial.
Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate age-related variations in baseline characteristics and reproductive outcomes among women with polycystic ovary syndrome (PCOS). Methods: A secondary analysis of the PCOSAct trial included 936 participants stratified into four age groups: 20-24, 25-29, 30-34, and 35-40 years. Differences in anthropometric measures, sex hormones, metabolic parameters, and pregnancy outcomes were analyzed using correlation and multiple logistic regression. Results: With increasing age, linear trends revealed increases in hirsutism score, systolic blood pressure, triglycerides, dyslipidemia, metabolic syndrome, and atherogenic indices (P-trend<0.05). Conversely, luteinizing hormone (LH), LH/FSH ratio, total testosterone, free testosterone, anti-Müllerian hormone (AMH), and HDL levels decreased (P-trend<0.05). Age independently correlated with these metabolic and endocrine shifts (all P<0.05). Advanced age was associated with higher ovulation induction success (adjusted OR = 1.058, 95% CI:1.006-1.114, P = 0.030) but also an increased risk of first-trimester threatened abortion (adjusted OR = 1.11, 95% CI:1.009-1.210, P = 0.031). No significant associations were observed with clinical pregnancy or live birth. Conclusion: The clinical presentation of PCOS evolves significantly with advancing age. It is typically characterized by a shift from a state of hyperandrogenism and reproductive abnormalities in younger women to a profile increasingly dominated by progressive metabolic disturbances and cardiovascular risks in later years. Although ovulation response improves in older patients, they face a higher risk of early pregnancy loss. This underscores the necessity of implementing age-stratified clinical management for individuals with PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.